{"id":"W4389234373","doi":"10.1182/blood-2023-178024","title":"Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Decitabine; Myelodysplastic syndromes; Pharmacokinetics; Chronic myelomonocytic leukemia; Hypomethylating agent; Pharmacology; Area under the curve; Internal medicine; Lenalidomide; Adverse effect; Oncology; International Prognostic Scoring System; Myeloid leukemia; Gastroenterology; Bone marrow","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004806002,0.0004041527,0.0005387628,0.0002224128,0.0002353301,0.0005309221,0.0004096368,0.0005089462,0.002908323],"category_scores_gemma":[0.000307524,0.0001779349,0.00043518,0.0001934582,0.0003854366,0.000411832,0.000294464,0.001580845,0.0004822449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004977031,"about_ca_system_score_gemma":0.0009463283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005860268,"about_ca_topic_score_gemma":0.001610072,"domain_scores_codex":[0.9998457,0.00004354667,0.000012826,0.00003370679,0.00003484607,0.00002934585],"domain_scores_gemma":[0.9998325,0.00001772865,0.00003204317,0.00001618362,0.00001515655,0.00008640417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1280709,0.04031409,0.01216858,0.001109181,0.0005892257,0.0005251574,0.0003940649,0.00477651,0.4232311,0.001716589,0.004393195,0.3827115],"study_design_scores_gemma":[0.1102218,0.6935697,0.0240361,0.000152716,0.0008039695,0.001760722,0.0001526662,0.004171715,0.1319976,0.0005484617,0.03254083,0.00004359383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892078,0.00311188,0.001300908,0.0003304858,0.0001083444,0.001247828,0.000404748,0.00008378068,0.004204239],"genre_scores_gemma":[0.992251,0.001506049,0.002453714,0.0003054238,0.00006102938,0.0007789124,0.0007759534,0.00001361876,0.001854301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002908323,"threshold_uncertainty_score":0.009729326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03044335139828663,"score_gpt":0.301529219538704,"score_spread":0.2710858681404174,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}